NCT04554914 2026-02-20
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
Pierre Fabre Medicament
Phase 2 Recruiting
Pierre Fabre Medicament
Viracta Therapeutics, Inc.
Cell Medica Ltd
Cell Medica Ltd
Celgene